Ghost Tree Capital’s PhaseBio Pharmaceuticals, Inc. Common Stock PHAS Stock Holding History

Ghost Tree Capital’s Portfolio PHAS Stock Details PHAS Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2020 Q2	–	Sell	-497,074	Closed	-$1.65M	–	55
2020 Q1	$1.65M	Buy	497,074 +47,074	+10%	+$215K	0.44%	40
2019 Q4	$2.75M	Buy	+450,000	New	+$1.85M	0.52%	41

Other funds holding PHAS

NMC

NEA Management Company Timonium, Maryland $1.76B AUM 223.33% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

JJIJ

Johnson & Johnson Innovation - JJDC New Brunswick, New Jersey $978M AUM 102.17% 1-Year Est. Return

RSCM

Rock Springs Capital Management Baltimore, Maryland $1.7B AUM 93.03% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

DCM

DAFNA Capital Management Los Angeles, California $440M AUM 109.12% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Ghost Tree Capital's PHAS Position: Q2 2020 in Review

Ghost Tree Capital sold out of PhaseBio Pharmaceuticals, Inc. Common Stock (PHAS) in Q2 2020, closing a stake of 497,074 shares — an estimated $1.65M sold.

Ghost Tree Capital first reported a position in PHAS in Q4 2019 and held it in 2 quarters. The position peaked at $2.75M in Q4 2019. 60 funds tracked by Wall St. Rank hold PHAS as of Q2 2020.

Ghost Tree Capital reported no remaining PhaseBio Pharmaceuticals, Inc. Common Stock position as of Q2 2020 after selling out during the quarter.
Ghost Tree Capital sold 497,074 PhaseBio Pharmaceuticals, Inc. Common Stock shares in Q2 2020, an estimated $1.65M.
Ghost Tree Capital first reported a position in PhaseBio Pharmaceuticals, Inc. Common Stock in Q4 2019 and held it in 2 quarters.
Ghost Tree Capital's PhaseBio Pharmaceuticals, Inc. Common Stock position peaked at $2.75M in Q4 2019.
60 funds tracked by Wall St. Rank held PhaseBio Pharmaceuticals, Inc. Common Stock as of Q2 2020.

Based on Ghost Tree Capital's 13F filing for Q2 2020, filed 14 Aug 2020.